Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the USA on 26th November 2019. The patent number is 10,488,530.
Related Posts
TRUEinvivo's DOSEmapper™ technology receives enthusiastic feedback from industry leaders at ESTRO37 conference.
TrueInvivo enhances cancer care with accurate, high-resolution in-vivo dosimetry system, optimizing radiotherapy outcomes.
Graduate secures vital government backing for innovative cancer treatment, targeting global markets with Sirius Programme.
TrueInvivo's implant improves cancer treatment accuracy, accessible globally, supported by UKTI Sirius Programme.
